Henrik Falhammar1,2, Jakob Skov1,3, Jan Calissendorff1,2, Jonatan D Lindh4, Buster Mannheimer5. 1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 2. Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden. 4. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden. 5. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Many drugs used in psychiatry have been reported to cause hyponatraemia. However, lithium may be an exception due to its potential for causing nephrogenic diabetes insipidus, but clinical data are largely absent. The objective of this investigation was to study the association between lithium therapy and hospitalization due to hyponatraemia. METHODS: This study was a register-based case-control investigation of the general Swedish population. Patients hospitalized with a principal diagnosis of hyponatraemia (n=11,213) were compared with matched controls (n=44,801). Analyses using multivariable logistic regression adjusting for co-medication, diseases, previous hospitalizations and socioeconomic factors were deployed to calculate the association between severe hyponatraemia and the use of lithium. Additionally, newly initiated (⩽90 days) and ongoing lithium therapy was studied separately. RESULTS: Compared with controls, the unadjusted odds ratio (OR) (95% confidence interval (CI)) for hospitalization due to hyponatraemia was 1.07 (0.70-1.59) for lithium. However, after adjustment for confounding factors the risk was reduced (adjusted OR: 0.53 (0.31-0.87)). Newly initiated lithium therapy was not significantly associated with hyponatraemia (adjusted OR 0.73 (0.35-5.38)). In contrast, for ongoing therapy the corresponding adjusted OR was significantly reduced (adjusted OR: 0.52 (0.30-0.87)). CONCLUSIONS: A marked inverse association was found between ongoing lithium therapy and hospitalization due to hyponatraemia.
BACKGROUND: Many drugs used in psychiatry have been reported to cause hyponatraemia. However, lithium may be an exception due to its potential for causing nephrogenic diabetes insipidus, but clinical data are largely absent. The objective of this investigation was to study the association between lithium therapy and hospitalization due to hyponatraemia. METHODS: This study was a register-based case-control investigation of the general Swedish population. Patients hospitalized with a principal diagnosis of hyponatraemia (n=11,213) were compared with matched controls (n=44,801). Analyses using multivariable logistic regression adjusting for co-medication, diseases, previous hospitalizations and socioeconomic factors were deployed to calculate the association between severe hyponatraemia and the use of lithium. Additionally, newly initiated (⩽90 days) and ongoing lithium therapy was studied separately. RESULTS: Compared with controls, the unadjusted odds ratio (OR) (95% confidence interval (CI)) for hospitalization due to hyponatraemia was 1.07 (0.70-1.59) for lithium. However, after adjustment for confounding factors the risk was reduced (adjusted OR: 0.53 (0.31-0.87)). Newly initiated lithium therapy was not significantly associated with hyponatraemia (adjusted OR 0.73 (0.35-5.38)). In contrast, for ongoing therapy the corresponding adjusted OR was significantly reduced (adjusted OR: 0.52 (0.30-0.87)). CONCLUSIONS: A marked inverse association was found between ongoing lithium therapy and hospitalization due to hyponatraemia.
Authors: Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson Journal: Am J Med Date: 2013-10 Impact factor: 4.965
Authors: Henrik Falhammar; Jan Calissendorff; Jakob Skov; David Nathanson; Jonatan D Lindh; Buster Mannheimer Journal: Eur J Intern Med Date: 2019-08-12 Impact factor: 4.487
Authors: Tessa S Schoot; Thomas H J Molmans; Koen P Grootens; Angèle P M Kerckhoffs Journal: Eur Neuropsychopharmacol Date: 2019-12-11 Impact factor: 4.600